This trial showed that a nutraceutical intervention based on high-dose vitamin D oral supplementation has no effect on hepatic fat content in T2D patients affected by NAFLD – 24-week cholecalciferol supplementation did not improve either transaminases levels or the serum levels of biomarkers specific for hepatic injury and fibrogenesis such as CK18-M30 and P3NP. This evidence concerns the gene KRT18 and metabolic dysfunction-associated steatotic liver disease.